Skip to main content

Advertisement

SpringerLink
Log in

Spasticity

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Treatment of spasticity requires a team approach, including the patient and caregivers, therapists, physicians, and surgeons. The team needs to determine what component of the spasticity interferes with function. Traditional therapy continues to dominate the therapy provided to patients who are living with spasticity. Treatment of increased tone must be part of the overall treatment plan for the patient. The plan may also include physical and occupational therapy, oral medication, injections of botulinum toxin, use of an intrathecal baclofen pump, or surgery. For patients with limited improvement from therapy, injections of botulinum toxin are often first-line treatment for focal spasticity involving overactive muscle groups. Botulinum toxin is safe when used at recommended doses and has limited side effects.

The benefits of oral medications in patients with focal spasticity may be limited by adverse effects at higher doses. Refractory spasticity may be treated with intrathecal baclofen. Surgery is reserved for patients in whom the other modalities fail to provide meaningful improvement. Continued communication from all members of the team can assure the best spasticity management plan for the individual patient, but patients need to have realistic expectations about outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gracies JM, Elovic E, Zorowitz R, et al.: Traditional pharmacologic treatments for spasticity. Part II: Systemic treatments. In Etiology, Evaluation, Management and the Role of Botulinum Toxin. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:79–110.

    Google Scholar 

  2. Barnes MP: Principles of neurological rehabilitation. J Neurol Neurosurg Psychiatry 2003, 74(Suppl 4):iv3–iv7.

    PubMed  Google Scholar 

  3. Meythaler JM, McCary A, Hadley MN: Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg 1997, 87:415–419.

    Article  PubMed  CAS  Google Scholar 

  4. Ward AB: A summary of spasticity management—a treatment algorithm. Eur J Neurol 2002, 9(Suppl 1):48–52.

    Article  PubMed  Google Scholar 

  5. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT: Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003, 84:103–107.

    Article  PubMed  Google Scholar 

  6. Brashear A, Gordon MF, Elovic E, et al.: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 347:395–400.

    Article  PubMed  CAS  Google Scholar 

  7. Simpson DM, Gracies JM, Graham HK, et al.: Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691–1698.

    Article  PubMed  CAS  Google Scholar 

  8. Childers MK, Brashear A, Jozefczyk P, et al.: Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004, 85:1063–1069.

    Article  PubMed  Google Scholar 

  9. Simpson DM, Alexander DN, O’Brien CF, et al.: Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306–1310.

    PubMed  CAS  Google Scholar 

  10. Gordon MF, Brashear A, Elovic E, et al.: Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004, 63:1971–1973.

    PubMed  CAS  Google Scholar 

  11. Bakheit AM, Pittock S, Moore AP, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001, 8:559–565.

    Article  PubMed  CAS  Google Scholar 

  12. Bakheit AM, Sawyer J: The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait—a pilot study. Disabil Rehabil 2002, 24:519–522.

    Article  PubMed  CAS  Google Scholar 

  13. Brashear A, Zafonte R, Corcoran M, et al.: Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002, 83:1349–1354.

    Article  PubMed  Google Scholar 

  14. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM: Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995, 59:562.

    Article  PubMed  CAS  Google Scholar 

  15. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM: Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000, 69:217–221.

    Article  PubMed  CAS  Google Scholar 

  16. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA: Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996, 61:30–35.

    Article  PubMed  CAS  Google Scholar 

  17. Bakheit AM, Fedorova NV, Skoromets AA, et al.: The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004, 75:1558–1561.

    Article  PubMed  CAS  Google Scholar 

  18. Katz RT, Rymer WZ: Spastic hypertonia: mechanisms and measurement. Arch Phys Med Rehabil 1989, 70:144–155.

    PubMed  CAS  Google Scholar 

  19. Pandyan AD, Cousins E, van WF, et al.: Spasticity research: some common catches. Arch Phys Med Rehabil 2005, 86:845–846.

    Article  PubMed  Google Scholar 

  20. Mayer N, Esquenazi A, Childers MK: Common patterns of clinical motor dysfunction. In Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:27–38.

    Google Scholar 

  21. Bakheit AM, Thilmann AF, Ward AB, et al.: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000, 31:2402–2406.

    PubMed  CAS  Google Scholar 

  22. Katz RT: Management of spasticity. Am J Phys Med Rehabil 1988, 67:108–116.

    Article  PubMed  CAS  Google Scholar 

  23. Allergan I. Package insert, BOTOX (Botulinum toxin Type A Purified Neurotoxin Complex). Irvine, CA: Allergan, Inc. 2000.

    Google Scholar 

  24. Physicians’ Desk Reference. Available at http://pdr.net/druginformation. Accessed November 2008.

  25. U.S. Food and Drug Administration: Early Communication about an Ongoing Safety Review: Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). Available at http://www.fda.gov/CDER/Drug/early_comm/botulinium_toxins.htm. Accessed February 17, 2009.

  26. Comella CL, Jankovic J, Shannon KM, et al.: Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65:1423–1429.

    Article  PubMed  CAS  Google Scholar 

  27. Brashear A: Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Investig Drugs 2001, 10:2191–2199.

    Article  PubMed  CAS  Google Scholar 

  28. Brashear A, McAfee AL, Kuhn ER, Fyffe J: Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004, 85:705–709.

    Article  PubMed  Google Scholar 

  29. Brashear A, Lew MF, Dykstra DD, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439–1446.

    PubMed  CAS  Google Scholar 

  30. Ward AB: Long-term modification of spasticity. J Rehabil Med 2003, 41(Suppl):60–65.

    Article  PubMed  Google Scholar 

  31. Coffey RJ, Edgar TS, Francisco GE, et al.: Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002, 83:735–741.

    Article  PubMed  Google Scholar 

  32. Botte MJ, Abrams RA, Bodine-Fowler SC: Treatment of acquired muscle spasticity using phenol peripheral nerve blocks. Orthopedics 1995, 18:151–159.

    PubMed  CAS  Google Scholar 

  33. Gracies JM, Elovic E, Zorowitz R, et al.: Traditional pharmacologic treatments for spasticity. Part 1: Local treatments. In Etiology, Evaluation, Management and the Role of Botulinum Toxin. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:57–78.

    Google Scholar 

  34. McGuire JR: Effective use of chemodenervation and chemical neurolysis in the management of poststroke spasticity. Top Stroke Rehabil 2001, 8:47–55.

    Article  PubMed  CAS  Google Scholar 

  35. Pill S, Keenan M: Neuro-orthopedic management of extremity dysfunction in patients with spasticity from upper motor neuron syndromes. In Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:119–141.

    Google Scholar 

  36. Lannin NA, Horsley SA, Herbert R, et al.: Splinting the hand in the functional position after brain impairment: a randomized, controlled trial. Arch Phys Med Rehabil 2003, 84:297–302.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC, 27157, USA

    Allison Brashear

Authors
  1. Allison Brashear
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly Lambeth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allison Brashear.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brashear, A., Lambeth, K. Spasticity. Curr Treat Options Neurol 11, 153–161 (2009). https://doi.org/10.1007/s11940-009-0018-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0018-4

Keywords

Search

Navigation